- Omeros is unique. It's different from other clinical-stage biotechs in that it has an FDA-approved drug (Omidria) in the market generating revenue to fund ongoing clinical developments.
- Now, the Omidria reimbursement overhang is gone after CMS confirmed a separate payment mechanism, which partially derisked the business.
- After years of struggle and almost no return to shareholders, Omeros finally sees the light at the end of the tunnel.
- The submitted narsoplimab BLA and upcoming approval could provide much higher upside potential.
For further details see:
Omeros: A Ripening Fruit Ready To Pick